Loading…
COMBIVENT RESPIMAT is a brand name for Albuterol (also known as Salbutamol), supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS…
Verbatim from this product's HC label. Tap a section to expand.
COMBIVENT RESPIMAT is contraindicated in: Patients with a history of hypersensitivity to any of its components or to atropine or its derivatives. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.
Patients with cardiac tachyarrhythmias, and hypertrophic obstructive cardiomyopathy. WARNINGS AND PRECAUTIONS General Systemic Effects In the following conditions COMBIVENT RESPIMAT should only be used after careful risk/benefit assessment: uncontrolled diabetes mellitus, recent myocardial infarction, severe organic heart or vascular disorders, hyperthyroidism, pheochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy, urinary retention.
Care should be taken with patients suffering from coronary insufficiency, arrhythmias and hypertension, convulsive disorders and in patients who are unusually responsive to sympathomimetic amines. Fatalities have been reported following excessive use of inhaled sympathomimetic amines, the exact cause of which is unknown.
Excessive Use and Use with other Sympaticomimetics or Muscarinic Antagonists As with other inhaled bronchodilators, COMBIVENT RESPIMAT should not be used more often or at higher doses than recommended. Concomitant use of COMBIVENT RESPIMAT with other sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects.
COMBIVENT RESPIMAT should not be administered concomitantly with other medicines containing a muscarinic antagonist, as this has not been studied, and an overdose may result (see DRUG INTERACTIONS). Anticholinergic Effects Like other anticholinergic drugs, COMBIVENT RESPIMAT should be used with caution in patients with narrow-angle glaucoma or urinary retention.
Worsening of Narrow-Angle Glaucoma:
COMBIVENT RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Care should be taken to avoid spraying the mist into the eyes. , mydriasis, increased intraocular pressure, narrow angle closure glaucoma, eye pain) when aerosolised ipratropium bromide either alone or in combination with an adrenergic beta2-agonist solution has come in contact with the eyes.
, eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from COMBIVENT RESPIMAT Product Monograph November 7, 2019 Page 5 of 44 conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Albuterol in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Miotic drops alone are not considered to be effective treatment.
Worsening of Urinary Retention:
COMBIVENT RESPIMAT should be used with caution in patients with urinary retention. , difficulty passing urine, painful urination). Instruct patients to consult a physician immediately should any of these signs or symptoms develop. Carcinogenesis and Mutagenesis Animal data only (see TOXICOLOGY Section).
Cardiovascular Special care and supervision are required in patients with idiopathic hypertrophic subvalvular aortic stenosis, in whom an increase in the pressure gradient between the left ventricle and the aorta may occur, causing increased strain on the left ventricle.
Cardiovascular effects in some patients, as measured by pulse rate, blood pressure, and/or symptoms may be seen with sympathomimetic drugs, including COMBIVENT RESPIMAT. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol, one of the components of COMBIVENT RESPIMAT.
In addition, beta-adrenergic agents like salbutamol, have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. Therefore, COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders; especially coronary insufficiency, cardiac arrhythmias, and hypertension.
ischaemic heart disease, arrhythmia or severe heart failure) who are receiving COMBIVENT RESPIMAT for respiratory disease should be warned to seek immediate medical advice if they experience chest pain or other symptoms of worsening heart disease.
Attention should be paid to assessment of symptoms as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin. Endocrine and Metabolism In common with other beta-adrenergic agents, salbutamol can induce reversible metabolic changes; these are more pronounced during infusions of the drug and include hyperglycemia and hypokalemia.
Potentially serious hypokalemia has been reported and can be aggravated by hypoxia. Hypokalemia will increase the susceptibility of digitalis-treated patients to cardiac arrhythmias. It is recommended that serum potassium levels be monitored in such situations.
Large doses of intravenous salbutamol have also been reported to aggravate pre-existing diabetes mellitus and may precipitate ketoacidosis. The relevance of these observations to the use of COMBIVENT RESPIMAT is unknown. COMBIVENT RESPIMAT Product Monograph November 7, 2019 Page 6 of 44 Gastrointestinal Patients with cystic fibrosis may be more prone to gastrointestinal motility disturbances.
Immune Hypersensitivity reactions including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema may occur after administration of ipratropium bromide or salbutamol sulfate. In clinical trials and post-marketing experience with ipratropium containing products, hypersensitivity reactions such as skin rash, pruritus, angioedema of tongue, lips and face, urticaria (including giant urticaria), laryngospasm and anaphylactic reactions have been reported (see […]